108 related articles for article (PubMed ID: 38206774)
1. Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients.
Argalácsová S; Křížová Ľ; Matějů M; Svobodová D; Vočka M
Folia Biol (Praha); 2023; 69(3):91-98. PubMed ID: 38206774
[TBL] [Abstract][Full Text] [Related]
2. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.
Chapman BV; Liu D; Shen Y; Olamigoke OO; Lakomy DS; Barrera AMG; Stecklein SR; Sawakuchi GO; Bright SJ; Bedrosian I; Litton JK; Smith BD; Woodward WA; Perkins GH; Hoffman KE; Stauder MC; Strom EA; Arun BK; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):437-444. PubMed ID: 34582940
[TBL] [Abstract][Full Text] [Related]
3. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
5. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
6. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
[TBL] [Abstract][Full Text] [Related]
7. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
8. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
[TBL] [Abstract][Full Text] [Related]
9. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
11. Germline pathogenic variants in metaplastic breast cancer patients and the emerging role of the BRCA1 gene.
Corso G; Marabelli M; Calvello M; Gandini S; Risti M; Feroce I; Mannucci S; Girardi A; De Scalzi AM; Magnoni F; Marino E; Bernard L; Veronesi P; Guerini-Rocco E; Barberis M; Guerrieri-Gonzaga A; Bonanni B
Eur J Hum Genet; 2023 Nov; 31(11):1275-1282. PubMed ID: 37460658
[TBL] [Abstract][Full Text] [Related]
12. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
13. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
[TBL] [Abstract][Full Text] [Related]
15. [GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN].
Michaelson-Cohen R; Laitman Y; Kedar I; Baris-Feldman H; Reish O; Lieberman S; Bernstein-Molho R; Goldberg Y; Reznick Levi G; Gershoni R; Beller U; Levy-Lahad E; Catan R; Friedman E
Harefuah; 2023 Jun; 162(6):370-375. PubMed ID: 37394440
[TBL] [Abstract][Full Text] [Related]
16. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.
Moreno M; Oliveira JS; Brianese RC; de Castro DG; Sanches SM; Torrezan GT; Santiago KM; De Brot M; Cordeiro de Lima VC; Baroni Alves Makdissi F; Casali Da Rocha JC; Calsavara VF; Carraro DM
Cancer Med; 2023 Aug; 12(15):16129-16141. PubMed ID: 37485802
[TBL] [Abstract][Full Text] [Related]
17. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
18. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
19. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
20. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]